ETF Holdings Breakdown of CGEM

CGEM institutional holdings

The adjusted close for CGEM on 2025-11-12 was 8.35

The following institutional investment holdings of CGEM have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	29,336	USD 244,956 6.6%	8.35
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	17,289 -0.3%	USD 144,363 6.3%	8.35
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	39,402	USD 329,007	8.35
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	39,402 0.3%	USD 329,007 6.8%	8.35
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	654	USD 5,461 6.6%	8.35
Total =		126,083	USD 1,052,794

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with CGEM

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of “Buy” by Brokerages

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned an average recommendation of “Buy” from the five research firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued ratings on the […] - 2025-08-28 02:56:53

Morgan Stanley Has Lowered Expectations for Cullinan Therapeutics (NASDAQ:CGEM) Stock Price

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) had its price target lowered by Morgan Stanley from $35.00 to $28.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 269.39% from the stock’s current price. […] - 2025-08-20 02:46:46

Exchange Traded Concepts LLC Has $107,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)

Exchange Traded Concepts LLC raised its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 42.6% during the 1st quarter, HoldingsChannel reports. The fund owned 14,107 shares of the company’s stock after purchasing an additional 4,216 shares during the period. Exchange Traded Concepts LLC’s holdings in Cullinan Therapeutics were worth $107,000 as […] - 2025-06-25 04:57:01

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short Interest

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) saw a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 5,990,000 shares, a drop of 19.9% from the April 30th total of 7,480,000 shares. Currently, 16.7% of the company’s shares are short sold. Based on an […] - 2025-06-02 05:08:54

Tower Research Capital LLC TRC Grows Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)

Tower Research Capital LLC TRC grew its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 411.3% during the 4th quarter, HoldingsChannel reports. The fund owned 8,800 shares of the company’s stock after buying an additional 7,079 shares during the period. Tower Research Capital LLC TRC’s holdings in Cullinan Therapeutics were worth […] - 2025-05-09 05:55:00

Wells Fargo & Company MN Acquires 8,056 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)

Wells Fargo & Company MN lifted its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 47.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,864 shares of the company’s stock after acquiring an additional 8,056 […] - 2025-05-07 04:24:54

Barclays PLC Sells 3,383 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)

Barclays PLC lowered its holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 1.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 245,231 shares of the company’s stock after selling 3,383 shares during the period. Barclays PLC’s holdings in Cullinan […] - 2025-04-30 05:50:47

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Legal & General Group Plc

Legal & General Group Plc decreased its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 7.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 42,808 shares of the company’s stock after selling 3,649 shares during the quarter. Legal & General Group Plc’s holdings in Cullinan Therapeutics were worth $521,000 as of […] - 2025-04-30 04:52:47

Brokerages Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) PT at $34.80

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the […] - 2025-04-30 02:34:45

23,500 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP bought a new stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 23,500 shares of the company’s stock, valued at approximately $286,000. Other hedge funds and other institutional investors also recently made changes […] - 2025-04-14 05:05:19

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Holdings Raised by American Century Companies Inc.

American Century Companies Inc. raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 11.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 100,721 shares of the company’s stock after buying an additional 10,010 shares during the period. American Century Companies Inc.’s holdings in Cullinan Therapeutics were worth […] - 2025-04-11 04:37:03

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,153 shares of the company’s stock, valued at approximately $136,000. Other large investors have […] - 2025-01-31 07:37:08

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Expected to Rise, HC Wainwright Analyst Says

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) had its price objective boosted by investment analysts at HC Wainwright from $28.00 to $33.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 200.55% from the stock’s […] - 2025-01-31 06:38:56

Back to Listing

Disclaimer